Are we reading different releases, this is only a daily dose trial. Standard treatment is 3x daily. P values at 3x are way better
"Having demonstrated protective efficacy in two published clinical studies (Otto et al., 2011), this Phase 2 study wasdesigned to compare the preventative effects of once daily dosing to the current standard recommended treatmentof three times daily dosing."
"Travelan® demonstrated clinical efficacy in preventing ETEC-attributable diarrhea in two previous CHIM studies. Thesestudies showed dosing 400 mg three times daily, resulted in 76.7% (p=0.007) to 90.9% (p=0.0005) protection (Otto etal., 2011)."
Ann: Travelan to progress to Phase 3 Clinical Trials in the US, page-41
-
- There are more pages in this discussion • 174 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
-0.010(9.09%) |
Mkt cap ! $22.79M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $46.94K | 448.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 124450 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 10000 | 1 |
View Market Depth
| Last trade - 15.58pm 02/08/2024 (20 minute delay) ? |
| IMC (ASX) Chart |